Pugliese Alberto, Boulware David, Yu Liping, Babu Sunanda, Steck Andrea K, Becker Dorothy, Rodriguez Henry, DiMeglio Linda, Evans-Molina Carmella, Harrison Leonard C, Schatz Desmond, Palmer Jerry P, Greenbaum Carla, Eisenbarth George S, Sosenko Jay M
Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL
Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL.
Diabetes. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28.
The HLA-DRB115:01-DQA101:02-DQB106:02 haplotype is linked to protection from the development of type 1 diabetes (T1D). However, it is not known at which stages in the natural history of T1D development this haplotype affords protection. We examined a cohort of 3,358 autoantibody-positive relatives of T1D patients in the Pathway to Prevention (PTP) Study of the Type 1 Diabetes TrialNet. The PTP study examines risk factors for T1D and disease progression in relatives. HLA typing revealed that 155 relatives carried this protective haplotype. A comparison with 60 autoantibody-negative relatives suggested protection from autoantibody development. Moreover, the relatives with DRB115:01-DQA101:02-DQB106:02 less frequently expressed autoantibodies associated with higher T1D risk, were less likely to have multiple autoantibodies at baseline, and rarely converted from single to multiple autoantibody positivity on follow-up. These relatives also had lower frequencies of metabolic abnormalities at baseline and exhibited no overall metabolic worsening on follow-up. Ultimately, they had a very low 5-year cumulative incidence of T1D. In conclusion, the protective influence of DRB115:01-DQA101:02-DQB1*06:02 spans from autoantibody development through all stages of progression, and relatives with this allele only rarely develop T1D.
HLA-DRB115:01-DQA101:02-DQB106:02单倍型与1型糖尿病(T1D)发病风险降低相关。然而,目前尚不清楚该单倍型在T1D自然病程的哪个阶段提供保护作用。我们在1型糖尿病试验网的预防途径(PTP)研究中,对3358名T1D患者自身抗体阳性的亲属进行了研究。PTP研究旨在探究T1D亲属的发病风险因素及疾病进展情况。HLA分型显示,155名亲属携带这种保护性单倍型。与60名自身抗体阴性的亲属相比,提示该单倍型对自身抗体产生有保护作用。此外,携带DRB115:01-DQA101:02-DQB106:02的亲属,与T1D高风险相关的自身抗体表达频率较低,基线时出现多种自身抗体的可能性较小,随访期间很少从单一自身抗体阳性转变为多种自身抗体阳性。这些亲属在基线时代谢异常的频率也较低,随访期间未出现整体代谢恶化。最终,他们的T1D 5年累积发病率非常低。总之,DRB115:01-DQA101:02-DQB1*06:02的保护作用贯穿自身抗体产生至疾病进展的各个阶段,携带该等位基因的亲属很少发展为T1D。